GLCE

Across TCGA pan-cancer cohorts, GLCE RNA is linked to patient survival in 24 of 34 cancer types, making it the most broadly survival-associated GLCE data layer compared with 9 for mutation status and 7 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher GLCE RNA is associated with worse overall survival. In most high-consensus cancer types, elevated GLCE expression acts as an unfavorable survival marker, although some lineages such as KIRC and PRAD show a favorable association.

MESO, KIRC, and BLCA are the cancer types where GLCE RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Quartile	All	0.249	0.548	.002	84	view →
KIRC	DFS	Median	All	0.724	0.543	<.001	80	view →
BLCA	DFS	Quartile	All	0.148	0.498	.004	44	view →
LGG	OS	Median	All	0.375	0.517	<.001	29	view →
SCLC	OS	Median	IV	0.219	0.729	.003	27	view →
ESCA	DFS	Median	IV	0.205	0.634	.006	24	view →
SKCM	DFS	Median	IV	0.220	0.666	.007	21	view →
PRAD	DFS	Tertile	All	0.965	0.905	.001	18	view →
BRCA	DFS	Tertile	III,IV	0.851	0.725	.023	16	view →
PAAD	OS	Tertile	All	0.482	0.751	.004	15	view →
CESC	DFS	Tertile	IV	0.249	0.625	.025	12	view →
READ	OS	Tertile	III,IV	0.952	0.335	.015	10	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 24 lineages.

GLCE–MESO (OS)

Open the MESO breakdown →